107 related articles for article (PubMed ID: 15629592)
1. Randomized trial of high- and low-source strength (125)I prostate seed implants.
Narayana V; Troyer S; Evans V; Winfield RJ; Roberson PL; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):44-51. PubMed ID: 15629592
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging.
Zelefsky MJ; Cohen G; Zakian KL; Dyke J; Koutcher JA; Hricak H; Schwartz L; Zaider M
Cancer J; 2000; 6(4):249-55. PubMed ID: 11038145
[TBL] [Abstract][Full Text] [Related]
3. AnchorSeed for the reduction of source movement in prostate brachytherapy with the Mick applicator implant technique.
Badwan HO; Shanahan AE; Adams MA; Shanahan TG; Mueller PW; Markwell SJ; Tarter TH
Brachytherapy; 2010; 9(1):23-6. PubMed ID: 19762286
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
7. Is an 192Ir permanent seed implant feasible for prostate brachytherapy?
Glasgow GP; Dogan N; Mohideen N
Brachytherapy; 2002; 1(4):195-203. PubMed ID: 15062167
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis.
Al-Qaisieh B; Smith DW; Brearley E; St Clair S; Bownes P
Radiother Oncol; 2007 Aug; 84(2):140-7. PubMed ID: 17588696
[TBL] [Abstract][Full Text] [Related]
9. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
10. Comparison of MRI- and CT-based post-implant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy.
Prete JJ; Prestidge BR; Bice WS; Dubois DF; Hotchkiss LA
Radiat Oncol Investig; 1998; 6(2):90-6. PubMed ID: 9572685
[TBL] [Abstract][Full Text] [Related]
11. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
[TBL] [Abstract][Full Text] [Related]
12. Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density.
Thomas CW; Kruk A; McGahan CE; Spadinger I; Morris WJ
Radiother Oncol; 2007 Apr; 83(1):18-24. PubMed ID: 17368844
[TBL] [Abstract][Full Text] [Related]
13. Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer.
Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook JM
Brachytherapy; 2008; 7(2):200-5. PubMed ID: 18362087
[TBL] [Abstract][Full Text] [Related]
14. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F
Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144
[TBL] [Abstract][Full Text] [Related]
15. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
16. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
[TBL] [Abstract][Full Text] [Related]
17. Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion.
Tanaka O; Hayashi S; Matsuo M; Nakano M; Uno H; Ohtakara K; Miyoshi T; Deguchi T; Hoshi H
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):614-8. PubMed ID: 17869675
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.
Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G
Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319
[TBL] [Abstract][Full Text] [Related]
19. Idealized line source configuration for permanent 125I prostate implants.
Leclerc G; Lavallée MC; Tubic D; Métivier J; Vigneault E; Beaulieu L
Radiother Oncol; 2004 Aug; 72(2):213-20. PubMed ID: 15297139
[TBL] [Abstract][Full Text] [Related]
20. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
